Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Overview 7 Therapeutics Development 8 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Stage of Development 8 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Therapy Area 9 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Indication 10 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Companies 13 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Products under Development by Universities/Institutes 15 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Companies Involved in Therapeutics Development 24 F. Hoffmann-La Roche Ltd. 24 Kringle Pharma, Inc. 25 Momenta Pharmaceuticals, Inc. 26 Ohr Pharmaceutical Inc. 27 Progen Pharmaceuticals Limited 28 Ribomic Inc. 29 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Drug Profiles 30 Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 CT-400 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CT-400P - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 GAL-F2 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 necuparanib - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 NK-4 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 PG-545 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 RBM-007 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Recombinant Protein to Inhibit FGF-2 for Cancer - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 squalamine lactate - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 TR-764 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Dormant Projects 53 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Discontinued Products 55 Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) - Featured News & Press Releases 56 Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 56 May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 56 May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee 57 Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA 58 Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program 58 Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program 59 Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 60 Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting 60 Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 61 Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology 61 Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 62 Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 63 May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 64 May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference 65 Apr 30, 2015: Ohr Pharmaceutical to Present at the 2015 Association for Research in Vision and Ophthalmology Conference in Denver, CO 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68

List of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 24 Pipeline by Kringle Pharma, Inc., H1 2016 25 Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 26 Pipeline by Ohr Pharmaceutical Inc., H1 2016 27 Pipeline by Progen Pharmaceuticals Limited, H1 2016 28 Pipeline by Ribomic Inc., H1 2016 29 Dormant Projects, H1 2016 53 Dormant Projects (Contd..1), H1 2016 54 Discontinued Products, H1 2016 55 List of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Routes of Administration, H1 2016 20 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 22

F. Hoffmann-La Roche Ltd. Kringle Pharma, Inc. Momenta Pharmaceuticals, Inc. Ohr Pharmaceutical Inc. Progen Pharmaceuticals Limited Ribomic Inc.